Iron Overload Exacerbates Busulfan-Melphalan Toxicity Through a Pharmacodynamic Interaction in Mice

[1]  Jacques Young,et al.  Correction: R31C GNRH1 Mutation and Congenital Hypogonadotropic Hypogonadism , 2013, PLoS ONE.

[2]  Jacques Young,et al.  R31C GNRH1 Mutation and Congenital Hypogonadotropic Hypogonadism , 2013, PloS one.

[3]  Jaana M. Hartikainen,et al.  Genetic polymorphisms and protein expression of NRF2 and Sulfiredoxin predict survival outcomes in breast cancer. , 2012, Cancer research.

[4]  A. Paci,et al.  Population Pharmacokinetics of Busulfan in Children–Letter , 2012, Clinical Cancer Research.

[5]  S. Broutin,et al.  Pharmacokinetic Behavior and Appraisal of Intravenous Busulfan Dosing in Infants and Older Children: The Results of a Population Pharmacokinetic Study From a Large Pediatric Cohort Undergoing Hematopoietic Stem-Cell Transplantation , 2012, Therapeutic drug monitoring.

[6]  M. Garami,et al.  Busulphan-melphalan as a myeloablative therapy (MAT) for high-risk neuroblastoma: Results from the HR-NBL1/SIOPEN trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  O. Cabaret,et al.  Effect of NFE2L2 Genetic Polymorphism on the Association Between Oral Estrogen Therapy and the Risk of Venous Thromboembolism in Postmenopausal Women , 2011, Clinical pharmacology and therapeutics.

[8]  Jacques Young,et al.  Familial Glucocorticoid Receptor Haploinsufficiency by Non-Sense Mediated mRNA Decay, Adrenal Hyperplasia and Apparent Mineralocorticoid Excess , 2010, PloS one.

[9]  A. Cacchione,et al.  Risk factors for hepatic veno-occlusive disease: a retrospective unicentric study in 116 children autografted after a high-dose BU-thiotepa regimen , 2008, Bone Marrow Transplantation.

[10]  A. L. Maître,et al.  Elevated Plasma Ferritin and Busulfan Pharmacodynamics During High‐dose Chemotherapy Regimens in Children with Malignant Solid Tumors , 2007, Clinical pharmacology and therapeutics.

[11]  S. Reddy,et al.  Functional polymorphisms in the transcription factor NRF2 in humans increase the risk of acute lung injury , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[12]  G. Vassal,et al.  Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring , 2007, Cancer Chemotherapy and Pharmacology.

[13]  P. Opolon,et al.  Induction of Glutathione Synthesis Explains Pharmacodynamics of High-Dose Busulfan in Mice and Highlights Putative Mechanisms of Drug Interaction , 2007, Drug Metabolism and Disposition.

[14]  J. Haines,et al.  The hemochromatosis C282Y allele: a risk factor for hepatic veno-occlusive disease after hematopoietic stem cell transplantation , 2005, Bone Marrow Transplantation.

[15]  L. Gordon,et al.  Rust and corrosion in hematopoietic stem cell transplantation: the problem of iron and oxidative stress , 2004, Bone Marrow Transplantation.

[16]  B. George,et al.  Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation. , 2004, Blood.

[17]  G. Vassal,et al.  In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa) , 2003, Bone Marrow Transplantation.

[18]  S. Biswal,et al.  Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. , 2002, Cancer research.

[19]  B. Green,et al.  Effect of polymorphism in the human glutathione S-transferase A1 promoter on hepatic GSTA1 and GSTA2 expression. , 2001, Pharmacogenetics.

[20]  F. Appelbaum,et al.  Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  S. Weitzman,et al.  Sequential changes in serum iron and ferritin in patients undergoing high-dose chemotherapy and radiation with autologous bone marrow transplantation: possible implications for treatment related toxicity. , 1995, Free radical biology & medicine.

[22]  G. Vassal,et al.  Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children. , 1992, Bone marrow transplantation.

[23]  G. Vassal,et al.  Is 600 mg/m2 the appropriate dosage of busulfan in children undergoing bone marrow transplantation? , 1992, Blood.

[24]  T. Mcelwain,et al.  Effect of high-dose melphalan on marrow and intestinal epithelium in mice pretreated with cyclophosphamide. , 1978, British Journal of Cancer.

[25]  L. Grochow,et al.  Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation , 2004, Cancer Chemotherapy and Pharmacology.

[26]  M. Dewhirst,et al.  Development of a model of melphalan-induced gastrointestinal toxicity in mice , 2004, Cancer Chemotherapy and Pharmacology.

[27]  G. Vassal,et al.  Gas chromatographic-mass spectrometric assay for busulfan in biological fluids using a deuterated internal standard. , 1988, Journal of chromatography.